X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com//news-release/2024/01/03/2803135/0/en/Apollomics-Completes-Enrollment-in-Phase-3-Bridging-Study-of-Uproleselan-in-Chinese-Patients-with-Relapsed-Refractory-Acute-Myeloid-Leukemia.html
https://www.clinicaltrialsarena.com/news/apollomics-doses-aml-trial/
https://www.globenewswire.com/news-release/2021/11/22/2338857/0/en/Apollomics-Inc-Doses-First-Patient-in-Phase-3-Clinical-Trial-with-APL-106-Uproleselan-Injection-in-Chinese-Patients-with-Relapsed-Refractory-Acute-Myeloid-Leukemia.html
https://seekingalpha.com/news/3743741-glycomimetics-shares-jump-12-after-highlighting-promising-data-from-uproleselan-leukemia-trial
https://www.globenewswire.com/fr/news-release/2021/01/07/2154803/0/en/APL-106-uproleselan-Granted-Breakthrough-Therapy-Designation-in-China-for-the-Treatment-of-Acute-Myeloid-Leukemia.html
Market Place
Share 
